Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier
|
|
- Cory Dixon
- 6 years ago
- Views:
Transcription
1 Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing Criteria Mucopolysaccharidosis type 3A (MPS3A, MPS llla)) Sanfilippo syndrome A Heparan sulfate sulfatase deficiency Sulfamidase deficiency MPS3A is one type of 4 related autosomal recessive lysosomal storage disorders caused by impaired degradation of heparan sulfate (found in the urine of affected patients). The first symptoms appear between the ages of 2 and 6 years, with behavioural disorders (hyperkinesia, aggressiveness) and intellectual deterioration, sleep disorders and very mild dysmorphism. The neurological involvement becomes more prominent around the age of 10 years with loss of motor milestones and communication problems. Seizures often occur after the age of 10. The prognosis is poor with death occurring in most cases of type IIIA at the end of the second decade. OMIM number for disease # Gene name and description (please provide any alternative names you wish listed) OMIM number for Gene * N-sulfoglucosamine sulfohydrolase (sulfamidase) (SGSH) MPS 3A is caused by deficiency of the N-sulfoglucosamine sulfohydrolase (SGSH) enzyme. Mutational spectrum for which you test Missense, nonsense and small insertion and deletion mutations identified throughout the gene. Currently 77 mutations of this type listed on the Human Gene Mutation Database, Cardiff ( Recurrent mutations have been described in certain populations (e.g. p.arg245his in 6/30 alleles tested in UK MPS 3A patients*). As published figures are based on low patient numbers and recurrent mutations appear to account for a small percentage of disease alleles we would not offer carrier testing to nonconsanguineous family members of MPS3A carriers. Given the low carrier frequency in the general population and in line with other services we do not feel that full sequencing of the coding region of the gene justified in non-consanguineous family members of MPS3A carriers. *Beesley C et al. (2000) JMG 37(9):704 Technical Method (s) Full sequencing testing of all 8 coding exons (in 9 fragments). Family mutations: PCR and restriction enzyme digest or sequencing 1
2 Validation Process Note please explain how this test has been validated for use in your laboratory Are you providing this test already? If yes, how many reports have you produced? Please give the number of mutation positive/negative samples you have reported For how long have you been providing this service? Is there specialised local clinical/research expertise for this disease? Are you testing for other genes/diseases closely allied to this one? Please give details Your Activity How many tests do you (intend to) provide annually in your laboratory? Based on experience how many tests will be required nationally (UK)? Please identify the information on which this is based Sequencing is a standard analytical method used in the laboratory for a range of diagnostic services requiring mutation detection. We successfully participate in EQA fro sequencing analysis. Analysis is conducted in accordance with CPA standards for which we are fully accredited Yes 4 x full screen, 14 x family mutation Carrier testing 2004 Full sequence testing 2005 Yes No Please provide details Great Ormond Street Hospital is one of several national centres designated by the National Commissioning Group to co-ordinate therapy for patients with various lysosomal storage disorders. Dr Clare Beesley, now working as a Clinical Scientist in our department, carried out research testing of patients with MPS3A at the Institute of Child Health, London (Beesley, C (2000) J Med Genet 37: ). The Biochemistry Department at Great Ormond Street Hospital has considerable expertise in the diagnosis of MPS3A (and other lysosomal storage disorders) Yes. We currently carry out testing for many other lysosomal storage disorders such as Fabry disease, Gaucher disease and Mucopolysaccharidosis types 1 and 2. We also test for MPS3 type B (NAGLU gene). Much of this testing was originally set up at the Institute of Child Health, London where there is considerable research experience. As mentioned above, there is also considerable clinical experience at Great Ormond Street Hospital of lysosomal disorders. Less than 5 confirmed cases diagnosed by enzyme analysis at Great Ormond Street Hospital per year. Other metabolic biochemistry / enzymology labs offering testing (a small number in the UK) likely to be the same or lower. Only biochemically confirmed cases will be tested. Testing has been offered since 2005 and 4 diagnostic referrals have been received. We would anticipate that several families tested on a research basis locally may require confirmatory testing in our lab. (Testing is also carried out by the Willink Biochemical Genetics Unit in Manchester as part of UKGTN.) 2
3 Epidemiology Estimated prevalence of disease in the general UK population Please identify the information on which this is based The incidence of Sanfilippo syndrome (A, B, C & D) has been estimated at (1) 1:24,000 in The Netherlands with MPS IIIA the most common. MPS-IIIA is the predominant MPS-III in the United Kingdom, and has a similar high incidence to that found in The Netherlands (E. Wraith, personal communication). Scott HS et al. Nat Genet Dec;11(4): (2) 1 in 86,000 Netherlands Poorthuis BJ et al. (1999) Hum Genet 105(1-2): (3) 1 in 58,000 - Western Australia with MPS3A accounting for around 50%. Nelson J et al. (2003) Am J Med Genet 123(3): p.ser66trp (c.197c>g), p.arg74cys (c.220c>t), p.arg245his (c.734g>a), c.1080delc (formerly 1091delC), c.1144_1145insagcgcc (formerly 1156ins6), and p.val486phe (c.1456g>t) may account for 56.5% of mutant alleles (not taking into account ethnic origin). p.arg245his has been shown to account for up to 20% of mutant alleles in UK patients (6/30 alleles). Beesley C et al. (2000) JMG 37(9):704 Estimated gene frequency (Carrier frequency or allele frequency) Please identify the information on which this is based Estimated penetrance Please identify the information on which this is based Target Population The essential clinical or family history features defining the target population must be described. The disorder is autosomal recessive. Estimating from Netherlands incidence figures (ref 1) carrier frequency would be around 1 in 150 There is a particularly high incidence of a clinically severe form of MPS-IIIA in the Cayman Islands with a carrier frequency of 0.1 Little published information. In cases with very low or absent enzyme activity (which would be the only cases we would accept) there is likely to be close to 100% penetrance. Full sequencing testing will be offered to patients with biochemically confirmed MPS3A (direct analysis of the SGSH enzyme) or parents of a confirmed MPS3A patient (where no DNA sample is available from the index case) (C)-Testing Criteria Estimated prevalence of disease in the target population Close to 100% in biochemically confirmed cases. We would recommend that biochemical testing is carried out in an experienced laboratory where direct enzyme analysis is possible to differentiate the four sub-types of MPS3 (types A, B, C & D). This expertise is available in the Chemical Pathology department, Great Ormond Street Hospital. 3
4 Intended Use (Please use the questions in Annex A to inform answers) your Please tick the relevant clinical purpose of testing Diagnosis Treatment Prognosis & Management Presymptomatic testing Risk Assessment YES NO Test Characteristics Analytical sensitivity and specificity This should be based on your own laboratory data for the specific test being applied for or the analytical sensitivity and specificity of the method/technique to be used in the case of a test yet to be set up. Direct sequencing has a high sensitivity in this laboratory. We use big dye chemistry, ABI analysers (3100, 3130XL, 3730) and analysis by eye / Mutation Surveyor software. We participate and perform successfully in EQA programmes for sequence analysis. If a number of genes will be tested, please include your testing strategy and data on the expected proportions of positive results for each part of the process. It may be helpful to include a diagram to illustrate the testing strategy. Clinical sensitivity and specificity of test in target population The clinical sensitivity of a test is the probability of a positive test result when disease is known to be present; the clinical specificity is the probability of a negative test result when disease is known to be absent. The denominator in this case is the number with the disease (for sensitivity) or the number without disease (for specificity) Little information available on mutation pickup in biochemically confirmed cases. Papers such as that by Beesley (Beesley, C (2000) J Med Genet 37: ) generally identify mutations in all patients tested using similar methods as that proposed in this document. 4
5 Clinical validity (positive and negative predictive value in the target population) The clinical validity of a genetic test is a measure of how well the test predicts the presence or absence of the phenotype, clinical disease or predisposition. It is measured by its positive predictive value (the probability of getting the disease given a positive test) and negative predictive value (the probability of not getting the disease given a negative test). The denominator in this case is the number of people with a positive or a negative test respectively - not the number with or without the disease. The clinical validity may be calculated knowing the sensitivity and the specificity and the prevalence of the disease in the population being studied. Positive and negative predictive values depend critically on the prevalence of the disease in the test population Clinical specificity very high in a patient with normal enzyme activity. All patients (index cases) tested will be biochemically confirmed as affected. 5
6 Clinical utility of test in target population (Please refer to Appendix A) Please provide a full description of the clinical care pathway for those individuals undergoing testing. This should include details of which medical specialties will be able to refer for testing. Testing would primarily be for disease confirmation, carrier testing, prenatal diagnosis and potentially PGD if appropriate. Treatment is mainly supportive (gene therapy is under investigation in animal models). (B)-Testing Criteria How will the test add to the management of the patient or alter clinical outcome? Primarily testing is focussed on carrier testing and future prenatal diagnosis. Genotype-phenotype correlations, should they become apparent, may provide information on the likely course of disease in some patients. What impact will this test have on the NHS i.e. by removing the need for alternative management and/or investigations for this clinical population? Carrier testing would be impossible without an identified mutation due to overlap of normal and carrier enzyme levels. Is there an alternative means of diagnosis or prediction that does not involve molecular diagnosis? If so (and in particular if there is a biochemical test) please state the added advantage of the molecular test Are there specific ethical, legal or social issues with this test? Enzymology is available and is a definitive test. However, mutation analysis may offer prognostic information and is the only reliable way of offering carrier testing. The ease of transport/storage of DNA samples may offer advantages over enzyme testing in prenatal diagnosis (where causative mutations have been identified). Common methods and reagents (i.e. not disease specific) are also used for all prenatal tests in this laboratory. No Please complete the referral pathway diagram on the following page and the testing criteria form. 6
7 Referral Pathway Template NOTE: Please use this page as a template. Please expand the test boxes manually as needed. TARGET POPULATION PATIENTS WITH BIOCHEMICALLY CONFIRMED MPS3A OR PARENTS OF BIOCHEMICALLY CONFIRMED CASE WHERE NO SAMPLE FROM THE INDEX CASE CAN BE OBTAINED Testing is not offered to unrelated partners of carriers WHAT TYPE AND LEVEL OF PROFESSIONAL OR REFERRER DO YOU ACCEPT SAMPLES FROM? CONSULTANT METABOLIC CLINICIAN CLINICAL GENETICIST PAEDIATRIC NEUROLOGIST PLEASE PROVIDE DETAILS OF HOW REFERRALS WILL BE ASSESSED FOR APPROPRIATENESS? Clinical scientist will confirm that biochemical confirmation of MPS3a has been obtained HOW MANY TESTS DO YOU EXPECT TO PERFORM ANNUALLY? National figure not known however only 4 diagnostic referrals received since
8 UKGTN Testing criteria: Name of Disease(s): MUCOPOLYSACCHARIDOSIS TYPE IIIA (252900) Name of gene(s): N-sulfoglucosamine sulfohydrolase (sulfamidase); SGSH (605270) Patient name: Patient postcode: Date of birth: NHS number: Name of referrer: Title/Position: Lab ID: Referrals will only be accepted from one of the following: Referrer Clinical Geneticists Metabolic Consultant Paediatric Neurologists Tick if this refers to you. Minimum criteria required for testing to be appropriate as stated in the Gene Dossier: Criteria Clinical diagnosis of MPS IIIA AND Proven decrease in N-sulfoglucosamine sulfohydrolase (SGSH) enzyme levels. At risk relatives where a family mutation has been found. Tick if this patient meets criteria If the sample does not fulfil the clinical criteria or you are not one of the specified types of referrer and you still feel that testing should be performed please contact the laboratory to discuss testing of the sample. 8
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Alagille syndrome 2 OMIM number for disease 610205 Disease alternative names please
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Cambridge RGC Approved: September 2012
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease 268800 Disease alternative names Please provide any alternative
More informationTREACHER COLLINS SYNDROME 2; TCS2 TREACHER COLLINS SYNDROME 3; TCS3 database (alternative names will be listed on the UKGTN website)
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Oxford RGC Approved: September 2012 1.
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Submitting laboratory: Edinburgh RGC 1. Disorder/condition approved name (please provide UK spelling
More informationMutation entries in SMA databases Guidelines for national curators
1 Mutation entries in SMA databases Guidelines for national curators GENERAL CONSIDERATIONS Role of the curator(s) of a national database Molecular data can be collected by many different ways. There are
More informationHow can genetic tests be evaluated for clinical use? Experience of the UK Genetic Testing Network
(2007) 15, 917 921 & 2007 Nature Publishing Group All rights reserved 1018-4813/07 $30.00 www.nature.com/ejhg ARTICLE Experience of the UK Genetic Testing Network Mark Kroese*,1, Ron L Zimmern 1, Peter
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease 147060 Disease alternative names please provide any alternative
More informationA Framework for Decision Making for Tests in the Scottish Molecular Pathology service. Date of issue: April 2015
A Framework for Decision Making for Tests in the Scottish Molecular Pathology service Date of issue: April 2015 Framework for Decision Making for Tests in the Scottish Molecular Pathology service Page
More informationTRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS
TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS THE DOORS ARE OPEN: FEEL FREE TO COME IN CENTOGENE UNLOCKS THE POWER OF GENETIC INSIGHTS TO IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH GENETIC
More informationMaternal mosaicism for IDUA deletion clarifies recurrence risk in MPS I.
Maternal mosaicism for IDUA deletion clarifies recurrence risk in MPS I. Catherine Breen 1, Jean Mercer 1, Simon A Jones 1, Amir Jahic 2, Lesley Heptinstall 1, Karen Tylee 1, William G Newman 1,* Christian
More informationExplain why the scientists used the same restriction endonuclease enzymes on each DNA sample
Q1.Some populations of flies are becoming resistant to insecticides intended to kill them. Scientists developed a method for finding out whether a fly was carrying a recessive allele, r, that gives resistance
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: London South East RGC GSTT Approved: September
More informationInformed Consent for Columbia Combined Genetic Panel (CCGP) for Adults Please read the following
Informed Consent for Columbia Combined Genetic Panel (CCGP) for Adults Please read the following form carefully and discuss with your ordering physician/genetic counselor before signing consent. 1. The
More informationNewborn Screening: It s Complicated! DNA testing in Newborn Screening
Newborn Screening: It s Complicated! DNA testing in Newborn Screening Denise M. Kay, Ph.D. NYS Newborn Screening Program Wadsworth Center, NYS DOH Why test DNA? Most conditions screened are genetic 25%
More informationACGS: Standardisation of variant interpretation and reports
ACGS: Standardisation of variant interpretation and reports Sian Ellard South West NHS Genomic Medicine Centre Festival of Genomics, 31 st January 2018 Genome sequencing for clinical diagnosis 2015 2018
More informationCystic Fibrosis. Gary Hoffman Wisconsin Newborn Screening Laboratory WISCONSIN STATE LABORATORY OF HYGIENE
Cystic Fibrosis Gary Hoffman Wisconsin Newborn Screening Laboratory Cystic Fibrosis Review Most common lethal genetic autosomal recessive disorder Caucasians 1:3,000 African Americans 1:20,000 Hispanics
More informationGenetics/Genomics in Public Health. Role of Clinical and Biochemical Geneticists in Public Health
Genetics/Genomics in Public Health Role of Clinical and Biochemical Geneticists in Public Health Premises Human variation is vast Strength of genetic factors are a continuum from low to high Testing technology
More informationMolecular Genetics of Disease and the Human Genome Project
9 Molecular Genetics of Disease and the Human Genome Project Fig. 1. The 23 chromosomes in the human genome. There are 22 autosomes (chromosomes 1 to 22) and two sex chromosomes (X and Y). Females inherit
More informationTotal urinary GAGs declined by 51%, dermatan sulfate by 32%, and heparan sulfate by 61% in Cohort 2 at 16 weeks
September 5, 2018 Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II
More informationCertification in Clinical Molecular Genetics and Genomics Logbook Guidelines for 2019 Examination
Certification in Clinical Molecular Genetics and Genomics Logbook Guidelines for 2019 Examination Purpose: The purpose of the logbook is to document that the applicant has had direct and meaningful involvement
More informationAS91159 Demonstrate understanding of gene expression
AS91159 Demonstrate understanding of gene expression Mutations and Metabolic Pathways (2015,2) In 1941 biologists George Beadle and Edward Tatum exposed the bread mould Neurospora crassa to radiation.
More informationREPRODUCTIVE HEALTH. Phosphorus. Diagnostics
14 32 6 32 7 REPRODUCTIVE HEALTH Phosphorus Diagnostics Genomics, Illuminated We focus on your peace of mind. Our expert-guided assay designs, powerful data analytics, and rigorous variant interpretation
More informationNiemann-Pick Type C Disease Gene Variation Database ( )
NPC-db (vs. 1.1) User Manual An introduction to the Niemann-Pick Type C Disease Gene Variation Database ( http://npc.fzk.de ) curated 2007/2008 by Dirk Dolle and Heiko Runz, Institute of Human Genetics,
More informationMOLECULAR GENETICS REPORT: Glycogen Storage Disease NextGen Sequencing Panel
Patient LAST, First ID#: DOB: Sex: CLIA #: 52D2065132 CAP #: 7185561 3800 S. Business Park Ave. Marshfield, WI 54449 Sample Information Type: Collected: Received: PG ID: Ordering Provider(s) MOLECULAR
More informationNASDAQ: ABEO
NASDAQ: ABEO www.abeonatherapeutics.com 1 Safe Harbor Statement This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933,
More informationExome Sequencing Exome sequencing is a technique that is used to examine all of the protein-coding regions of the genome.
Glossary of Terms Genetics is a term that refers to the study of genes and their role in inheritance the way certain traits are passed down from one generation to another. Genomics is the study of all
More informationCustom Panels via Clinical Exomes
Custom Panels via Clinical Exomes Andrew Wallace Feb 2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester Custom Panel via Exome Approach Pros Reduced validation overhead Single validation
More informationAMERICAN BOARD OF MEDICAL GENETICS
AMERICAN BOARD OF MEDICAL GENETICS Logbook Guidelines for Certification in Clinical Molecular Genetics for the 2015 Examination Purpose: The purpose of the logbook is to document that the applicant has
More informationHandbook. Precautions/warnings: For professional use only. To support clinical diagnosis. Not yet offered in the US. Page 1
Handbook Precautions/warnings: For professional use only. To support clinical diagnosis. Not yet offered in the US. Page 1 CentoMDx TM 1.1_Handbook_V1.1_March2018 Contents Introduction... 3 Intended use...
More informationIntegrated Course of HUMAN AND MEDICAL GENETICS
Integrated Course of HUMAN AND MEDICAL GENETICS Scientific Fields: MEDICAL GENETICS (MED/03) APPLIED BIOLOGY (BIO/13) European Credit Transfer and Accumulation System = 7 Coordinator: Prof. BRUNELLA FRANCO,
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease Disease alternative names Please provide any alternative
More informationCreativity in a Government Health Service: the challenge and the triumph
ATSE Health Forum: Friday 22 nd November 2013 Creativity in a Government Health Service: the challenge and the triumph therapeutics for lysosomal storage disorder patients John J Hopwood Lysosomal Diseases
More informationCertification in Laboratory Genetics and Genomics Logbook Guidelines 2019 Examination
Certification in Laboratory Genetics and Genomics Logbook Guidelines 2019 Examination Purpose: The purpose of the logbook is to document that the applicant has had direct and meaningful involvement in
More informationSi mon P t e ersen J ones
Simon Petersen Jones What is a DNA based Test Uses sample of DNA Blood Cheek Swab Identifies the genotype (not phenotype) of the animal There are Two Categories of Test: Mutation Detection Direct detection
More informationAmerican Board of Medical Genetics and Genomics
American Board of Medical Genetics and Genomics Logbook Guidelines for Certification in Laboratory Genetics and Genomics for the 2019 Examination as of 11/10/2016 Purpose: The purpose of the logbook is
More informationMolecular Pathology Coding Workgroup Fly-In
Molecular Pathology Coding Workgroup Fly-In What CPT Is Role of Current Procedural Terminology Nomenclature: Coding CPT is a listing of descriptive terms and identifying codes for reporting medical services
More informationProduced by the Centre for Genetics Education. Internet: 5
Important points Genes are made of DNA The information in the DNA is in the form of a chemical code made up of four letters (A, T, C and G). Each word in the information is made up of three of these four
More informationBiol 321 Spring 2011 Final Exam Info/Data Sheet NAME. You MUST RETURN this sheet with your Exam. Section 1 Problem 7
Biol 321 Spring 2011 Final Exam Info/Data Sheet NAME You MUST RETURN this sheet with your Exam Autosomal Recessive 1. trait appears in progeny of unaffected parents 2. the trait breeds true and both sexes
More informationGenomics for All: From 100,000 genomes to a national NHS Genomic Medicine Service
Genomics for All: From 100,000 genomes to a national NHS Genomic Medicine Service Professor Dame Sue Hill @CSOsue Chief Scientific Officer for England SRO Genomics, NHS England September 2018 Genomics:
More informationDuchenne Muscular Dystrophy
Duchenne Muscular Dystrophy Clinical and Commercial Strategy Dr. Leslie Hudson, President and CEO September 10, 2008 Duchenne Muscular Dystrophy (DMD) Defects in the dystrophin gene; no protein expression
More informationPATIENT INFORMATION CLINICAL INFORMATION TEST REQUESTED FIRST NAME MI LAST NAME MAIDEN NAME BIRTH DATE GENDER RACE ETHNICITY. Yes
REQUEST FOR NON-SYNDROMIC PORT-WINE STAINS AND STURGE-WEBER SYNDROME TESTING Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS
More informationPharmacogenetics: A SNPshot of the Future. Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001
Pharmacogenetics: A SNPshot of the Future Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001 1 I. What is pharmacogenetics? It is the study of how genetic variation affects drug response
More information6th Form Open Day 15th July 2015
6th Form Open Day 15 th July 2015 DNA is like a computer program but far, far more advanced than any software ever created. Bill Gates Welcome to the Open Day event at the Institute of Genetic Medicine
More informationGenetics 101: What does it mean to have an LBSL-specific mutation
Genetics 101: What does it mean to have an LBSL-specific mutation Rebecca McClellan, MGC, CGC Johns Hopkins Center for Inherited Heart Disease Kennedy Krieger Metabolism Clinic Genetics 101 A gene is the
More informationMolecular diagnosis of haemophilia and other bleeding disorders
Molecular diagnosis of haemophilia and other bleeding disorders Jayandharan G Rao Associate Professor Department of Haematology Christian Medical College Vellore, India. Jayandharan et al, J Genet Synd
More informationHuether and McCance: Understanding Pathophysiology, 5 th Edition
Huether and McCance: Understanding Pathophysiology, 5 th Edition Chapter 02: Genes and Genetic Diseases Test Bank MULTIPLE CHOICE 1. A nurse recalls the basic components of DNA are: a. Pentose sugars and
More informationMolecular Analysis to Enhance Newborn Screening.. March 1, 2016 Michele Caggana, Sc.D., FACMG February 29, 2016
Molecular Analysis to Enhance Newborn Screening.. March 1, 2016 Michele Caggana, Sc.D., FACMG February 29, 2016 March 1, 2016 2.Are You Ready to Jump In?? March 1, 2016 3 Population Based Risk Assessment
More informationProduct Sheet Huntington Disease Genemer Control DNA*
Product Sheet Huntington Disease Genemer Control DNA* *Specific control DNA for use with Gene Link Genemer & GeneProber product lines Catalog No. 40-2025-XX For research use only. Not for use in diagnostic
More informationUpdates on Issues in Molecular Genetics Testing
Updates on Issues in Molecular Genetics Testing Iris Schrijver, MD Stanford University November 19, 2009 Overview Inheritance Results HDGC Molecular Pathology Molecular Techniques Clinical Criteria and
More informationUnderstanding Gene Therapy. April 26, 2016
Understanding Gene Therapy April 26, 2016 To avoid any technical difficulties and to listen in without any problems, please login through WebEx first before calling in. You may be able to call in through
More informationREQUEST FOR HEMOPHILIA B (FACTOR IX DEFICIENCY)
REQUEST FOR HEMOPHILIA B (FACTOR IX DEFICIENCY) Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS PATIENT INFORMATION* FIRST
More informationExpansion of Newborn Screening in Wisconsin and Beyond
Expansion of Newborn Screening in Wisconsin and Beyond Charles Brokopp, DrPH Director, Wisconsin State Laboratory of Hygiene Professor, Population Health Sciences School of Medicine and Public Health 2012
More informationDifferential Diagnosis Between 3-MCC Deficiency and Holocarboxylase Synthetase Deficiency Facilitated by the Strand Clinical Exome Test
CASE STUDY Differential Diagnosis Between 3-MCC Deficiency and Holocarboxylase Synthetase Deficiency Facilitated by the Strand Clinical Exome Test Introduction Inborn errors of metabolism (IEM) are congenital
More informationPerformance of the Newly Developed Non-Invasive Prenatal Multi- Gene Sequencing Screen
1 // Performance of the Newly Developed Non-Invasive Prenatal Multi- Gene Sequencing Screen ABSTRACT Here we describe the analytical performance of the newly developed non-invasive prenatal multi-gene
More informationi. This type of DNA damage will result in (circle all correct answers) b. a transversion mutation
Biol 321 Winter 2010 Quiz 5 40 points NAME ANSWERS IN RED COMMENTS IN BLUE 1. (2 pts.) Recall the article entitled: Human Genetic Variation By each statement circle True/False/Not addressed in the paper.
More informationThe implementation of laboratory investigations for diagnosing. pyruvate kinase deficiency at the Johannesburg Hospital
The implementation of laboratory investigations for diagnosing pyruvate kinase deficiency at the Johannesburg Hospital Pierre Durand (Student no: 8604833/H) A report submitted to the Faculty of Health
More informationPunnett Square with Heterozygous Cross (Video clip) There is a glaring error with this video clip. Can you spot it???
Section 3: Studying Heredity Objectives Predict the results of monohybrid genetic crosses by using Punnett squares. Apply a test cross to determine the genotype of an organism with a dominant phenotype.
More informationBiochemical Genetics Laboratory Hospital Marie Jackson Consultant Clinical Scientist
Biochemical Genetics Laboratory Viapath @Guys Hospital Marie Jackson Consultant Clinical Scientist Measurement uncertainty Produced document stating our approach to measurement uncertainty in Biochemical
More informationThe 100,000 Genomes Project Genomics Collaboration Event Finnish Residence
The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence Prof Mark Caulfield FMedSci Chief Scientist for Genomics England Barts Heart Centre William Harvey Research Institute Queen Mary
More informationTargeted Sequencing in the NBS Laboratory
Targeted Sequencing in the NBS Laboratory Christopher Greene, PhD Newborn Screening and Molecular Biology Branch Division of Laboratory Sciences Gene Sequencing in Public Health Newborn Screening February
More informationOrphaNews Europe: Can you describe some of the activities and projects the Myrovlytis Trust is funding?
In 2007, patients with Birt-Hogg-Dube syndrome got a new guardian angel: the Myrovlytis Trust. This London-based charity was initiated and funded in late 2007 by an anonymous source. It was registered
More informationTorreya acted as exclusive financial advisor to Lysogene. About MPS IIIA and LYS-SAF302
Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
More information-- Expands Sarepta s portfolio to as many as 14 gene therapy programs --
Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
More informationSenior Clinical Investigator
Senior Clinical Investigator 2009-2014 Elfride De Baere Center for Medical Genetics, Ghent University, Belgium http://www.cmgg.be FKM symposium Brussels 20 November 2014 Curriculum vitae 1989-1996 02.07.1996
More informationGENETIC ANALYSIS REPORT
GENETIC ANALYSIS REPORT OWNER S DETAILS Lauren Sikkema 8055 Concession 6 Moorefield N0G2K0 CA ANIMAL S DETAILS Registered Name: Pet Name: Eve Registration Number: Breed: Australian Cobberdog Microchip
More informationAn innovative approach to genetic testing for improved patient care
An innovative approach to genetic testing for improved patient care Blueprint Genetics Blueprint Genetics is changing diagnostics by providing fast, affordable and comprehensive genetic knowledge Who we
More informationBIOL 225 Genetics-Final Exam November 17, 2006 Dr. Sandra Davis
BIOL 225 Genetics-Final Exam November 17, 2006 Dr. Sandra Davis INSTRUCTIONS: 1. Read the questions carefully and write your answers in the space provided. If you need more space, clearly indicate WHERE
More informationPolymerase Chain Reaction (PCR) and Its Applications
Polymerase Chain Reaction (PCR) and Its Applications What is PCR? PCR is an exponentially progressing synthesis of the defined target DNA sequences in vitro. It was invented in 1983 by Dr. Kary Mullis,
More informationJumping Into Your Gene Pool: Understanding Genetic Test Results
Jumping Into Your Gene Pool: Understanding Genetic Test Results Susan A. Berry, MD Professor and Director Division of Genetics and Metabolism Department of Pediatrics University of Minnesota Acknowledgment
More informationWARM UP. 1. Take out your laptop and Chapter 12 Notes 2. Log in to Google Classroom 3. Wait for me to post the quick quiz!
WARM UP 1. Take out your laptop and Chapter 12 Notes 2. Log in to Google Classroom 3. Wait for me to post the quick quiz! AGENDA Warm up- Quick Quiz Chapter 13 Notes: Genetic Technology Genetic Engineering
More informationPolicy Number: Title: Abstract Purpose: Policy Detail:
- 1 - Policy Number: N04202 Title: NHP/NHIC-Medical Policy-Genetic, Genotype and Genomic Testing Abstract Purpose: The purpose of this policy to provide guidance for decisions related to genetic, genotype
More informationTarget Enrichment Strategies for Next Generation Sequencing
Target Enrichment Strategies for Next Generation Sequencing Anuj Gupta, PhD Agilent Technologies, New Delhi Genotypic Conference, Sept 2014 NGS Timeline Information burst Nearly 30,000 human genomes sequenced
More information2. (So) get (fragments with gene) R / required gene. Accept: allele for gene / same gene 2
M.(a). Cut (DNA) at same (base) sequence / (recognition) sequence; Accept: cut DNA at same place. (So) get (fragments with gene) R / required gene. Accept: allele for gene / same gene (b). Each has / they
More informationCorporate Medical Policy Genetic Testing for Fanconi Anemia
Corporate Medical Policy Genetic Testing for Fanconi Anemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_fanconi_anemia 03/2015 3/2017 3/2018 12/2017 Description
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationSema4 CarrierCheck Informed Consent
Sema4 CarrierCheck Informed Consent [last modified July 20, 2017] This informed consent describes the benefits, risks, and limitations of undergoing DNA testing for certain genetic conditions with Sema4
More informationNovel Presentation of Cornelia de Lange Syndrome: Holoprosencephaly with Colpocephaly
CASE STUDY Novel Presentation of Cornelia de Lange Syndrome: Holoprosencephaly with Colpocephaly Introduction Delayed developmental milestones and abnormal development are significant causes of concern
More informationPresented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego
Presented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego Discuss the difference between DNA Genotyping and Genome Sequencing What makes you who you
More informationThe 100,000 Genomes Project Rare Disease Programme
The 100,000 Genomes Project Rare Disease Programme Dr Richard Scott Clinical Lead for Rare Disease, Genomics England Consultant in Clinical Genetics, Great Ormond Street The 100,000 Genomes Project History
More informationClinician s Guide to Actionable Genes and Genome Interpretation
Clinician s Guide to Actionable Genes and Genome Interpretation Brandy Bernard PhD Senior Research Scientist Institute for Systems Biology Seattle, WA Dr. Bernard s research interests are in cancer drug
More information23andMe Personal Genome Service (PGS) Genetic Health Risk Report Package Insert BRCA1/BRCA2 (Selected Variants)
23andMe Personal Genome Service (PGS) Genetic Health Risk Report Package Insert /BRCA2 (Selected Variants) Table of contents Indications for use Summary and explanation of the test Important considerations
More informationGenetic testing of Tay-Sachs disease by PCR and Restriction Digest
Genetic testing of Tay-Sachs disease by PCR and Restriction Digest ESC102-PRA0103 Submitted to: Elizabeth Berndl 18 February, 2009 Submitted by: Laila Hulbert (996625077) Maria Yancheva (996742173) Scientific
More informationHST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007
MIT OpenCourseWare http://ocw.mit.edu HST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.
More informationProcess and guidelines for applications for approval of trials involving gene and other biotechnology therapies. November 2015
Process and guidelines for applications for approval of trials involving gene and other biotechnology therapies November 2015 HRC Gene Technology Advisory Committee For further information contact: Professor
More informationProofreading and Correction
How about a mistake? Just as we make mistakes, so can the replication process Wrong bases may be inserted into the new DNA Nucleotide bases may be damaged (ie. By radiation) When this happens, mutations
More informationGenetics and Genomics in Clinical Research
Genetics and Genomics in Clinical Research An Immersion Course for Clinical Investigators at UAB Introduction and Overview Bruce R. Korf, MD, PhD Goals Describe approaches to study of the genomic contributions
More informationGenetic Technologies.notebook March 05, Genetic Technologies
Genetic Testing Genetic Technologies Tests can be used to diagnose disorders and/or identify those individuals with an increased risk of inheriting a disorder. Prenatal Screening A fetus may be screened
More informationThe patient must address the treating physician directly if he/she has any questions or requires information regarding the test results.
Order Form 1. Ordering of the FoundationOne Service The FoundationOne Service comprises the genetic analysis of tumour tissue and the compilation of a comprehensive report on any mutations found in the
More informationIntroduction to Basic Human Genetics. Professor Hanan Hamamy Department of Genetic Medicine and Development Geneva University Switzerland
Introduction to Basic Human Genetics Professor Hanan Hamamy Department of Genetic Medicine and Development Geneva University Switzerland Training Course in Sexual and Reproductive Health Research Geneva
More informationNewborn screening for spinal muscular atrophy
Newborn screening for spinal muscular atrophy Kristina Mercer, MPH, PhD ORISE Fellow Newborn Screening Translational Research Initiative Newborn Screening and Molecular Biology Branch APHL Newborn Screening
More informationCharacterization of novel rare genetic variants identified by next generation sequencing
Characterization of novel rare genetic variants identified by next generation sequencing Maja Stojiljković, PhD Institute of Molecular Genetics and Genetic Engineering University of Belgrade RARE DISEASES
More informationFIRST NAME MI LAST NAME BIRTH DATE (MM/DD/YYYY) GENDER. Specify countries: Name of person previously tested and relationship:
REQUEST FOR SITE SPECIFIC ANALYSIS [APC / MYH / TP53 / MLH1 / MSH2 / MSH6] Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS
More informationGen e e n t e i t c c V a V ri r abi b li l ty Biolo l gy g Lec e tur u e e 9 : 9 Gen e et e ic I n I her e itan a ce
Genetic Variability Biology 102 Lecture 9: Genetic Inheritance Asexual reproduction = daughter cells genetically identical to parent (clones) Sexual reproduction = offspring are genetic hybrids Tendency
More informationBefore starting, write your name on the top of each page Make sure you have all pages
Biology 105: Introduction to Genetics Name Student ID Before starting, write your name on the top of each page Make sure you have all pages You can use the back-side of the pages for scratch, but we will
More informationPractical 4: PCR in Molecular Diagnosis
PRINCIPLES What is PCR Practical 4: PCR in Molecular Diagnosis Instructors: Dr. Valerie C.L. Lin and Dr. Sze Chun Chau PCR stands for polymerase chain reaction. The PCR method was devised and named by
More informationGenetic Testing in the Clinic. Anne Goodeve Sheffield Diagnostic Genetics Service Sheffield Children s NHS Foundation Trust
Genetic Testing in the Clinic Anne Goodeve Sheffield Diagnostic Genetics Service Sheffield Children s NHS Foundation Trust Disclosures for Anne Goodeve In compliance with COI policy, ISTH requires the
More information2001 Research Grants. Research Update 1. First Year Update-Canine MPS IIIB Haskins 2002
2001 Research Grants Research Update 1 First Year Update-Canine MPS IIIB Haskins 2002 "A Proposal to Develop a Canine Model of MPS IIIB". Mark Haskins, VMD, PhD, and Matthew Ellinwood, DVM, PhD, School
More information